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Polymyxin-based photosensitizer for the potent
and selective killing of Gram-negative bacteria†
Muhammed Ucuncu,‡a Bethany Mills, ‡b Sheelagh Duncan,b Matteo Staderini,a
Kevin Dhaliwalb and Mark Bradley *a
Here we report the synthesis of a novel methylene blue-polymyxin
conjugate and demonstrate its light-mediated killing of Gram-
negative bacteria on skin models of infection demonstrating a
108 decrease in bacterial colony-forming units.
Infectious diseases are one of the leading causes of morbidity
and mortality globally1,2 and during the 20th century, major
advances in the discovery and development of antibiotics led to
improved survival from bacterial infections.3 However, overuse,
misuse and environmental factors have led to a global increase
in antimicrobial resistance (AMR). As such the development of
new treatment strategies are imperative to combat the rise in
antimicrobial resistance and to help sustain modern medical
practice, with the pivotal need to develop strategies that cannot
give rise to resistance.4,5
Photodynamic therapy (PDT) is widely utilised for the treat-
ment of solid tumours, psoriasis, a variety of dental applications
and surface decontamination.6–10 PDT utilizes a photosensitizer
(PS) which is activated by light to produce highly reactive oxygen
species (ROS), including hydroxyl radicals (Type I photo-
process) and singlet oxygen (Type II photo-process).11
However, the potential scope of PDT extends to a broad
spectrum of targets, including pathogens (bacteria, fungi and
viruses), where its mode of action would be unlikely to give rise
to resistance.12–14 Thus over the last two decades, photo-
dynamic inactivation strategies to kill bacteria have been
investigated,13–15 however they have often suffered from poor
selectivity and antimicrobial PDT has not been widely adopted
in the clinic in large part due to the lack of bacterial targeting
photo-sensitising agents.14,16–18 Several attempts to improve the
selectivity and sensitivity of antimicrobial PDT have been reported.
The most common approaches have involved co-application of a
PS together with a membrane disorganising agent or with the PS
covalently coupled to a targeting unit.19–23 However, studies have
typically explored antimicrobial PDT against planktonic bacteria,
rather than those within more clinically relevant infections.14,24
This is important as in biofilms bacteria are located within an
extracellular polymer matrix, where there is often poor drug
penetration and reduced killing efficacy, with the minimum
biofilm eradication concentration of the antimicrobial agent
often 100-fold higher than the standard minimum inhibitory
concentration.25 Thus the aim of this study was to design,
synthesise and validate a novel antimicrobial PDT agent that
exhibits high selectivity and sensitivity against Gram-negative
bacteria, including those within biofilms.
In the design of our Gram-negative antimicrobial PDT agent,
we utilised polymyxin B that had been modified to remove its
hydrophobic tail and adapted with a photosensitizer that would
give high killing efficiency while offering low dark toxicity
(Scheme 1). Polymyxin B (PMX-B) is a non-ribosomal cyclic
lipopeptide antibiotic, increasingly utilised to treat Gram-
negative bacterial infections. The mechanism of action is dual
fold and is based on the electrostatic interaction of the protonated
g-amino units in the cyclic heptapeptide with the negatively
charged lipopolysaccharides of the bacterial outer membrane
and anchoring of the hydrophobic fatty acid tail and the D-Phe
and L-Leu units through insertion into the outer membrane. This
bivalent, entropically driven binding disrupts cell membrane
integrity and results in cell lysis.26 Previously, Nitzan et al. showed
the synergistic effect of polymyxin on antimicrobial photodynamic
therapy27 while Guern used a polymyxin B scaffold as a targeting
unit.28,29 In their study, a cationic porphyrin (as the photo-
sensitizer) was coupled to polymyxin B via thiol maleimide
chemistry, however their probe lost specificity and killed both
Gram-positive and negative bacteria, perhaps due to the fact
that thiol maleimide chemistry is reversible or the non-selective
nature of cationic porphyrins to bacteria. In our antimicrobial
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PDT agent design we selected methylene blue (MB) which is an
FDA approved photosensitizer with high photo-stability and red
shifted absorbance (providing slighter deeper light penetration),
while having high singlet oxygen (and other reactive oxygen
species) quantum yields.30
Probe synthesis began by removing the hydrophobic tail of
PMX-B using papain.31 The side chains of the five L-diamino-
butyric acid residues were protected using Boc-ON31 allowing
selective amide coupling chemistry to attach both a small poly-
ethylene glycol spacer (using Fmoc-NH-(EG)2-CH2-COOH using
DIC) and methylene blue which had been functionalised with a
carboxylic acid group (using HSPyU) (Scheme 2 and Scheme S2,
ESI†). The antimicrobial photodynamic therapy agent MB-PMX,
was obtained after TFA deprotection of the Boc groups and HPLC
purification (ESI†). The carboxylic acid derivative of methylene blue
(MB-COOH) was prepared as previously reported32 via reaction of
N-methyl aniline and ethyl 4-bromobutyrate followed by hydrolysis.
The product, N-methyl-N-(carboxypropyl)aniline, was treated with
the 2-amino-5-(dimethylamino)phenylthio-sulfonic acid (prepared
from 4-(N,N0-dimethyl)aniline) to give MB-COOH in moderate over-
all yield (B25%).
MB-PMX showed very similar absorption and emission features
to that of unconjugated MB (Fig. 1a and b) with an absorption
maxima at 670 nm with a weak emission centred around 694 nm
upon excitation at 610 nm (10 mM in Saline (0.9% NaCl)). The
robustness of MB-PMX (50 mM in 0.9% NaCl) was investigated with
illumination at 630 nm, 10 mW cm2 over 60 min and showed
excellent photo-stability with its absorbance only decreasing by
10% during 60 min of irradiation. As expected, increasing the
power to 40 mW cm2 (for 60 min) resulted in more significant
photo bleaching but still 60% of the probe survived (Fig. S3, ESI†).
The singlet oxygen generation ability of MB-PMX was
assessed using diphenylisobenzofuran (DPBF), which quickly
traps singlet oxygen via endo-peroxide formation (that sub-
sequently decomposes to 1,2-dibenzoylbenzene).33 Mixtures of
MB-PMX (5 mM) and DPBF (50 mM) were continuously irradiated
and the decrease in absorbance measured at 415 nm (Fig. 1c).
The absorbance band of DPBF disappeared within a few
minutes with a measured singlet oxygen quantum yield of
fD = 0.4 (using MB as the reference photosensitizer with fD =
0.5).11 The ability of the probe to generate other reactive oxygen
species (i.e. superoxide) via type I photo-process was explored
using dihydrorhodamine 123 (DHR 123) (10 mM in water).34 In
this case the increase in fluorescence emission at 526 nm was
monitored (lex = 500 nm) and as shown in Fig. 1d increased
with irradiation time, validating that MB-PMX produces both
singlet oxygen and other ROS via type I and type II mechanisms.
The sensitivity, specificity and phototoxicity of MB-PMX was
explored against a panel of pathogenic bacteria using Gram-
negative Escherichia coli and Pseudomonas aeruginosa, with
Staphylococcus aureus as a Gram-positive control. Unsurpris-
ingly there was no reduction in CFU for any strain with just
illumination (Fig. 2a and Fig. S6, ESI†), and for S. aureus there
was no reduction under any condition, including MB-PMX plus
illumination, indicating that MB-PMX was unable to bind to
Gram-positive bacteria and elicit a phototoxic effect. With
E. coli and P. aeruginosa, 100% killing (108 fold reduction in
CFU mL1) was achieved following 10 min MB-PMX exposure
and illumination (Fig. 2a and Fig. S6, ESI†). Transmission
Scheme 1 Mode of action of the bacterial targeting antimicrobial photo-
dynamic therapy agent MB-PMX.
Scheme 2 Synthetic route to MB-PMX.
Fig. 1 (a) Absorbance spectra of MB and MB-PMX (10 mM in saline (0.9%
NaCl)). (b) Excitation (dashed line) and emission (solid line) spectra of MB
and MB-PMX (10 mM in saline (0.9% NaCl)). (c) Decrease in absorbance of
the singlet oxygen trap (DPBF) at 415 nm (MB-PMX (5 mM) and DPBF
(50 mM) in methanol, 630 nm, 1.5 mW cm2). (d) Increase in the fluorescence
signal of ROS trap molecule DHR 123 (MB-PMX (10 mM) and DHR 123 (10 mM)
in water at different time points (t = 0, 5, 10, 15, 20, 25, 30 min) 630 nm,
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electron microscopy (TEM) of the bacterial samples showed
membrane disruption (blebbing) with a total breakdown of the
bacterial cell wall following MB-PMX exposure and illumination
(Fig. 2b). Whilst MB-PMX was able to perturb the cell membrane
of Gram-negative bacteria following illumination, no disruption
to the cell wall of S. aureus or haemolysis of human red blood
cells was observed following equivalent illumination in the
presence of excess MB-PMX, at concentrations of up to 10 fold
of those used in our planktonic bacteria studies (Fig. 2b and
Fig. S7, ESI†).
Compared to MB-PMX, the independent killing efficiency of
MB and PMX-B was poor when added to the cultures together
followed by irradiation. Indeed, there was no killing effect
mediated by MB (10 mM) alone. PMX-B alone (10 mM) did
exhibit bactericidal effect on planktonic E. coli and P. aeruginosa
under the same conditions with a 102 fold reduction in
CFU mL1 for E. coli, and a 105 reduction in CFU mL1 observed
for P. aeruginosa. P. aeruginosa was also susceptible to MB-PMX
without illumination, with a 103 fold reduction in CFU mL1
measured, indicating that the polymyxin domain of our PDT
agent was still active and potent. However, as demonstrated the
MB-PMX conjugate with illumination gave complete microbial
killing demonstrating excellent selectivity and sensitivity at low
concentrations and was far superior to the MB plus PMX-B
strategy (for further explanation see Fig. S6, ESI†).
Antimicrobial photodynamic therapy is an approach well
suited to surface infections, such as those associated with the
skin, or for the treatment of surfaces prior to surgical interventions
such as orthopaedic implants. This has the added benefit of
topical application of PDT photosensitizes mitigating against
potential unwanted cytotoxic affects, often associated with
systemic delivery of antimicrobials. To assess the feasibility of
our antibacterial PDT approach, we utilised a porcine skin
model of an early stage E. coli infection, similar to that utilised
by Maisch et al.35 and assessed the efficacy of MB-PMX (Fig. 3).
Porcine skin samples were excised using a biopsy punch and
stabilised within an agarose mount before being inoculated
with E. coli. MB-PMX was added and the sample irradiated
(Fig. 3a) (or maintained in the dark as a control). The tissue was
homogenised, and bacterial levels quantified (Fig. 3b). MB-PMX
in the dark did not elicit any antibacterial effect, however MB-
PMX (10 mM) with illumination resulted in bacterial killing,
eliciting an 11-fold reduction in bacterial count, whilst complete
killing of the bacteria was observed with 50 mM MB-PMX
treatment and 2 h illumination.
Early E. coli biofilms were established and their composition
of bacteria (3D, non-motile aggregates and extracellular matrix
deposition) confirmed by scanning electron microscopy (Fig. 3c
and Fig. S8, ESI†). We observed complete killing of E. coli biofilms
Fig. 2 (a) Colony forming units (CFU) of Gram-negative (black bars) and
Gram-positive (grey bars) bacteria with 10 mM MB and/or 10 mM PMX-B
(solid bars) or MB-PMX (10 mM, dashed bars), following 10 min illumination
at 630 nm, 10 mW cm2. No illumination and/or no photosensitiser served as
controls. Error bars show s.e.m., analysed by student t-test with comparison
to bacteria-only control: ****P o 0.0001; **P o 0.001. n Z 3 repeats.
(b) Transmission electron microscopy (TEM) of E. coli, P. aeruginosa and
S. aureus post PDT treatment with 10 mm MB-PMX and 10 min illumination at
630 nm, 10 mW cm2. Controls were irradiated without MB-PMX. Images
captured with 12 000 magnification, scale bar = 500 nm.
Fig. 3 (a) Image of infected porcine skin punches undergoing PDT.
(b) Colony forming units (CFU) recovered from infected porcine skin post
treatment with MB-PMX and illumination 630 nm, 40 mW cm2 for 2 h.
Error bars show s.e.m. Analysed by one-way ANOVA comparison to
illumination only control: **P = 0.0079, **P = 0.0046. n = 5, performed
in duplicate. (c) Representative SEM image of E. coli biofilms grown and
treated by PDT with MB-PMX. Scale bar = 2 mm. (d) Colony forming units
(CFU) recovered from E. coli biofilms following treatment with MB-PMX
and illumination at 630 nm, 40 mW cm2. Analysed by one-way ANOVA
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with MB-PMX in a dose and time dependent manner, with a 108
reduction in CFU mL1 achieved with 50 mM MB-PMX and 2 hours
of illumination (630 nm, 40 mW cm2) (Fig. 3d). Even with as little
as 10 mM MB-PMX and 1 h illumination, a 50% reduction in
bacterial biofilm viability was achieved, demonstrating the potency
of our Gram-negative specific PDT agent.
In conclusion, we have developed a novel antimicrobial
photodynamic therapy agent, MB-PMX, which demonstrates
selective and potent photodynamic bactericidal activity against
Gram-negative bacteria, with efficacy against clinical isolates of
E. coli and P. aeruginosa. Not only did MB-PMX show out-
standing antimicrobial PDT activity against planktonic bacteria
with 100% pathogen killing with short light irradiation times
but it also demonstrated the ability to treat biofilms and
infected skin models, whilst having no effect on Gram-positive
S. aureus or human erythrocytes. Here we have demonstrated
potency against early, mono-species biofilms and infections, and
thus further evaluation of complex multispecies biofilm and skin
wounds is warranted to further elucidate the potential role of
PDT with MB-PMX as an alternative to antimicrobial treatments.
The targeting effect of the polymyxin ligand ensures that the
killing functionality of the reactive oxygen species is not only
highly localised (where it can induce the most damage), but is
also concentrated on the target itself – leading to much higher
therapeutic efficacies.
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